65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) at 24 Hours After a Single-dose of Study Treatment — 0.916; 0.986; 1.015; 1.029 L — p=0.0005
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level — 10.8; 15.2; 9.42; 13.5 ng/mL
Leukemia
Primary: Rate of Disease Free Survival at One Year — 50 percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.008; 0.189; 0.213; 0.213 Liter — p=<0.0001
Obstructive Sleep Apnea
Primary: Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of >50% and Treated AHI<20 — 26 subjects with clinical success
Cystic Fibrosis
Primary: Change in Mucociliary Clearance Rate — 2.77; -2.35 percent clearance
MPS IV A
Primary: Subject Incidence of Treatment Emergent AEs — 18; 18; 17; 17 participants
Hemispatial Neglect
Primary: Change From Baseline in Star Cancellation Test Scores at 1,3, and 6 Months — 17.88; 18.20; 20.03; 5.90 units on a scale — p=0.77
Chronic Myeloid Leukemia
Primary: Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population — 67.4; 25.8; 8.7; 41.0 percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.054; 0.131; 0.152; 0.119 Liter — p=<0.0001
Plaque Psoriasis Patients
Primary: Number of Weeks of Etanercept Treatment — 48.1874 weeks
Spinal Cord Injury
Primary: Quality of Bowel Preparation — 3.4; 2.5; 3.6; 7.4 units on a scale
Dry Eye
Primary: Mean Change From Baseline in Tear Break-up Time (TBUT) at 60 Minutes — 1.2; 1.2 seconds
Infiltration of Peripheral IV Therapy
Primary: Red Notification Sensitivity to Infiltrated Tissues — 96.4 percentage of infiltrations
Alzheimer's Disease · Agitation
Primary: NeuroBehavior Rating Scale-- Agitation — 4.33; 5.26 units on a scale — p=0.036